The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance☆
Open accessAbstract
BACKGROUND & AIMS: Significant improvements in management of hepatocellular carcinoma (HCC) have occurred in the last years, but their impact on surveillance outcome is unknown. To clarify this, we compared survival of HCC patients identified along 3 consecutive quinquennia of surveillance. METHODS: A cohort of 417 HCC-free outpatients with compensated cirrhosis was prospectively followed for 148 months (range, 1-213 months) with periodic ultrasound examinations. RESULTS: HCC developed in 112 patients, at a 3.4% rate per year, and was the prime cause of death (n = 54). Forty-six (41%) patients had a single tumor, with a mean size of 3.7 cm, 3.0 cm, and 2.2 cm in the 3 quinquennia (first vs. second: ns; first vs. third: P = 0.017; second vs. third: P = 0.02), and 38 (44%) underwent radical therapy. Mortality rates in HCC patients fell from 45% in the first quinquennium to 37% in the second and 10% in the third (first vs. second: ns; first vs. third: P = 0.0009; second vs. third: P = 0.018) in parallel with a reduction in yearly mortality of treated patients (34%, 28%, and 5%, respectively; first vs. second: ns; second vs. third: P = 0.036; first vs. third: P = 0.0024). After stratification for quinquennium, tumor staging, according to Cancer of the Liver Italian Program (CLIP), was the only independent predictor of survival (P = 0.015). CONCLUSIONS: Cirrhotic patients developing a HCC during the last 5 years of surveillance survived longer than previously, as a consequence of improved management of the tumor and complications of cirrhosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transection of the oesophagus for bleeding oesophageal varices
Pugh, R. N. H., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C., & Williams, R. (1973) · Journal of British Surgery · doi:10.1002/bjs.1800600817 · Cited by 7,941 · cited 1×
“0 29 4 (40) 5 (83) 10 (45) 9 (47) 0 1 (2) 1 45 3 (30) 0 9 (41) 7 (37) 5 (45.5) 21 (48) 2 27 2 (20) 1 (17) 3 ( 14 ) 3 (16) 5 (45.5) 13 (30) 3 9 1 (10) 0 0 0 1 (9) 7 (16) 4 2 0 0 0 0 0 2 (4) All 112 10 (100) 6 (100) 22 (100) 19 (100) 11 (100) 44 (100)”
InfluentialMazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,186
Self-citationClinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference
Bruix, J., Sherman, M., Llovet, J. M., Beaugrand, M., Lencioni, R., Burroughs, A. K., Christensen, E., Pagliaro, L., Colombo, M., & Rodés, J. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00130-1 · Cited by 4,089
Self-citationSmall Hepatocellular Carcinoma: Treatment with Radio-frequency Ablation versus Ethanol Injection
Livraghi, T., Goldberg, S. N., Lazzaroni, S., Meloni, F., Solbiati, L., & Gazelle, G. S. (1999) · Radiology · doi:10.1148/radiology.210.3.r99fe40655 · Cited by 1,283
A new prognostic system for hepatocellular carcinoma: A retrospective study of 435 patients
(1998) · Hepatology · doi:10.1002/hep.510280322 · Cited by 1,238
Bruix, J., Castells, A., Bosch, J., Feu, F., Fuster, J., Garcia-Pagan, J., Visa, J., Bru, C., & Rodes, J. (1996) · Gastroenterology · doi:10.1016/s0016-5085(96)70070-7 · Cited by 895
Hepatocellular Carcinoma in Italian Patients with Cirrhosis
Colombo, M., de Franchis, R., Del Ninno, E., Sangiovanni, A., De Fazio, C., Tommasini, M., Donato, M. F., Piva, A., Di Carlo, V., & Dioguardi, N. (1991) · New England Journal of Medicine · doi:10.1056/nejm199109053251002 · Cited by 813
Self-citationTyping of hepatitis C virus isolates and characterization of new subtypes using a line probe assay
Stuyver, L., Rossau, R., Wyseur, A., Duhamel, M., Vanderborght, B., Van Heuverswyn, H., & Maertens, G. (1993) · Journal of General Virology · doi:10.1099/0022-1317-74-6-1093 · Cited by 685
Bolondi, L., Sofia, S., Siringo, S., Gaiani, S., Casali, A., Zironi, G., Piscaglia, F., Gramantieri, L., Zanetti, M., & Sherman, M. (2001) · Gut · doi:10.1136/gut.48.2.251 · Cited by 643
Performance status assessment in cancer patients. An inter-observer variability study
Sørensen, J., Klee, M., Palshof, T., & Hansen, H. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.140 · Cited by 483
Cited by
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
“On the other hand, cohort comparisons of 6 versus 12-month schemes provide similar results [52,92], while retrospective studies identified better performance of the 6-month interval in terms of stage migration (small HCC amenable for curative treatments) [96] and survival [97].”
ResultThe biology and function of fibroblasts in cancer
Kalluri, R. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.73 · Cited by 4,366
Hepatocellular carcinoma in cirrhosis: Incidence and risk factors
Fattovich, G., Stroffolini, T., Zagni, I., & Donato, F. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.014 · Cited by 2,591
Molecular therapies and precision medicine for hepatocellular carcinoma
Llovet, J. M., Montal, R., Sia, D., & Finn, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0073-4 · Cited by 1,938
Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma
Llovet, J. M., Di Bisceglie, A. M., Bruix, J., Kramer, B. S., Lencioni, R., Zhu, A. X., Sherman, M., Schwartz, M., Lotze, M., Talwalkar, J., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn134 · Cited by 1,653
Fattovich, G., Bortolotti, F., & Donato, F. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.11.011 · Cited by 1,348
Tzartzeva, K., Obi, J., Rich, N. E., Parikh, N. D., Marrero, J. A., Yopp, A., Waljee, A. K., & Singal, A. G. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.01.064 · Cited by 1,207
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
(2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.021 · Cited by 1,096
Forner, A., Vilana, R., Ayuso, C., Bianchi, L., Solé, M., Ayuso, J. R., Boix, L., Sala, M., Varela, M., Llovet, J. M., et al. (2008) · Hepatology · doi:10.1002/hep.21966 · Cited by 1,032
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling
Lee, J.-S., Chu, I.-S., Heo, J., Calvisi, D. F., Sun, Z., Roskams, T., Durnez, A., Demetris, A. J., & Thorgeirsson, S. S. (2004) · Hepatology · doi:10.1002/hep.20375 · Cited by 922
Conti, F., Buonfiglioli, F., Scuteri, A., Crespi, C., Bolondi, L., Caraceni, P., Foschi, F. G., Lenzi, M., Mazzella, G., Verucchi, G., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.06.015 · Cited by 897
Resection and Liver Transplantation for Hepatocellular Carcinoma
Llovet, J. M., Schwartz, M., & Mazzaferro, V. (2005) · Seminars in Liver Disease · doi:10.1055/s-2005-871198 · Cited by 879
SINGAL, A., VOLK, M. L., WALJEE, A., SALGIA, R., HIGGINS, P., ROGERS, M. A. M., & MARRERO, J. A. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04014.x · Cited by 819
Novel advancements in the management of hepatocellular carcinoma in 2008
Llovet, J. M., & Bruix, J. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2008.01.022 · Cited by 815
Garofalo, M., Di Leva, G., Romano, G., Nuovo, G., Suh, S.-S., Ngankeu, A., Taccioli, C., Pichiorri, F., Alder, H., Secchiero, P., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.10.014 · Cited by 733
RetractedPivotal Role of mTOR Signaling in Hepatocellular Carcinoma
Villanueva, A., Chiang, D. Y., Newell, P., Peix, J., Thung, S., Alsinet, C., Tovar, V., Roayaie, S., Minguez, B., Sole, M., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.08.008 · Cited by 733
MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma
Fornari, F., Gramantieri, L., Ferracin, M., Veronese, A., Sabbioni, S., Calin, G. A., Grazi, G. L., Giovannini, C., Croce, C. M., Bolondi, L., et al. (2008) · Oncogene · doi:10.1038/onc.2008.178 · Cited by 639
Global trends and predictions in hepatocellular carcinoma mortality
Bertuccio, P., Turati, F., Carioli, G., Rodriguez, T., La Vecchia, C., Malvezzi, M., & Negri, E. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.011 · Cited by 632
Sangiovanni, A., Prati, G. M., Fasani, P., Ronchi, G., Romeo, R., Manini, M., Del Ninno, E., Morabito, A., & Colombo, M. (2006) · Hepatology · doi:10.1002/hep.21176 · Cited by 628
Self-citationBowen, T., Cicardi, M., Farkas, H., Bork, K., Longhurst, H. J., Zuraw, B., Aygoeren-Pürsün, E., Craig, T., Binkley, K., Hebert, J., et al. (2010) · Allergy, Asthma & Clinical Immunology · doi:10.1186/1710-1492-6-24 · Cited by 614
de Lope, C. R., Tremosini, S., Forner, A., Reig, M., & Bruix, J. (2012) · Journal of Hepatology · doi:10.1016/s0168-8278(12)60009-9 · Cited by 610
Chemoembolization for hepatocellular carcinoma
Bruix, J., Sala, M., & Llovet, J. M. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.09.032 · Cited by 569
Colli, A., Fraquelli, M., Casazza, G., Massironi, S., Colucci, A., Conte, D., & Duca, P. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00467.x · Cited by 540
Local-Regional Treatment of Hepatocellular Carcinoma
Lencioni, R., & Crocetti, L. (2012) · Radiology · doi:10.1148/radiol.11110144 · Cited by 514
Loco‐regional treatment of hepatocellular carcinoma†
Lencioni, R. (2010) · Hepatology · doi:10.1002/hep.23725 · Cited by 509
Updated treatment approach to hepatocellular carcinoma
Llovet, J. M. (2005) · Journal of Gastroenterology · doi:10.1007/s00535-005-1566-3 · Cited by 508
Sangiovanni, A., Manini, M. A., Iavarone, M., Romeo, R., Forzenigo, L. V., Fraquelli, M., Massironi, S., Della Corte, C., Ronchi, G., Rumi, M. G., et al. (2010) · Gut · doi:10.1136/gut.2009.187286 · Cited by 408
Self-citationKorean Liver Cancer Association, K., & National Cancer Center, N. (2019) · Gut and Liver · doi:10.5009/gnl19024 · Cited by 391
Llovet, J. M., Chen, Y., Wurmbach, E., Roayaie, S., Fiel, M. I., Schwartz, M., Thung, S. N., Khitrov, G., Zhang, W., Villanueva, A., et al. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.09.014 · Cited by 386
Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies
Tandon, P., & Garcia‐Tsao, G. (2009) · Liver International · doi:10.1111/j.1478-3231.2008.01957.x · Cited by 354
The changing epidemiology of liver diseases in the Asia–Pacific region
Wong, M. C. S., Huang, J. L. W., George, J., Huang, J., Leung, C., Eslam, M., Chan, H. L. Y., & Ng, S. C. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0055-0 · Cited by 344
LOPEZ, P. M., VILLANUEVA, A., & LLOVET, J. M. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02932.x · Cited by 344
2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0294 · Cited by 343
Changing epidemiology of hepatocellular carcinoma in Asia
Zhang, C., Cheng, Y., Zhang, S., Fan, J., & Gao, Q. (2022) · Liver International · doi:10.1111/liv.15251 · Cited by 335
Stigliano, R., Marelli, L., Yu, D., Davies, N., Patch, D., & Burroughs, A. K. (2007) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.04.001 · Cited by 311
Germani, G., Pleguezuelo, M., Gurusamy, K., Meyer, T., Isgrò, G., & Burroughs, A. K. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2009.12.004 · Cited by 304
Santi, V., Trevisani, F., Gramenzi, A., Grignaschi, A., Mirici-Cappa, F., Poggio, P. D., Nolfo, M. A. D., Benvegnù, L., Farinati, F., Zoli, M., et al. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.03.010 · Cited by 304
MicroRNA involvement in hepatocellular carcinoma
Gramantieri, L., Fornari, F., Callegari, E., Sabbioni, S., Lanza, G., Croce, C. M., Bolondi, L., & Negrini, M. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00533.x · Cited by 304
Epidemiology of Hepatocellular Carcinoma
Lafaro, K. J., Demirjian, A. N., & Pawlik, T. M. (2015) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2014.09.001 · Cited by 303
Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease
Loria, P., Adinolfi, L. E., Bellentani, S., Bugianesi, E., Grieco, A., Fargion, S., Gasbarrini, A., Loguercio, C., Lonardo, A., Marchesini, G., et al. (2010) · Digestive and Liver Disease · doi:10.1016/j.dld.2010.01.021 · Cited by 294
Cirrhosis and its complications: Evidence based treatment
Nusrat, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i18.5442 · Cited by 285
Trends in mortality from hepatocellular carcinoma in Europe, 1980‐2004†
Bosetti, C., Levi, F., Boffetta, P., Lucchini, F., Negri, E., & La Vecchia, C. (2008) · Hepatology · doi:10.1002/hep.22312 · Cited by 280
Cherqui, D., Laurent, A., Mocellin, N., Tayar, C., Luciani, A., Van Nhieu, J. T., Decaens, T., Hurtova, M., Memeo, R., Mallat, A., et al. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181bd582b · Cited by 278
Yu, S. J. (2016) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2016.22.1.7 · Cited by 273
Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma
Oliveri, R. S., Wetterslev, J., & Gluud, C. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004787.pub2 · Cited by 268
Review article: the management of hepatocellular carcinoma
CABRERA, R., & NELSON, D. R. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04200.x · Cited by 222
Metadata
- Authors
- Sangiovanni, A., Del Ninno, E., Fasani, P., De Fazio, C., Ronchi, G., Romeo, R., Morabito, A., de Franchis, R., & Colombo, M.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2004-04
- Volume
- 126
- Issue
- 4
- Pages
- 1005-1014
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2131212067
- Cited by
- 600
- References
- 23
- FWCI
- 21.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.